Cargando…

Randomized trial on acute toxicities of weekly vs three‐weekly cisplatin‐based chemoradiation in head and neck cancer

BACKGROUND: The current first‐line treatment of locally advanced head and neck carcinoma (LAHNC) is concurrent chemoradiation with three‐weekly cisplatin 100 mg/m(2). However, prescribing cisplatin at this dose increases the treatment toxicity, which may compromise the treatment results. An alternat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ameri, Ahmad, Norouzi, Shokoufe, Sourati, Ainaz, Azghandi, Samira, Novin, Kambiz, Taghizadeh‐Hesary, Farzad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789619/ https://www.ncbi.nlm.nih.gov/pubmed/34101389 http://dx.doi.org/10.1002/cnr2.1425

Ejemplares similares

Weekly vs. tri-weekly cisplatin based chemoradiation in carcinoma cervix: a prospective randomized study of toxicity and compliance
por: Katke, Aradhana, et al.
Publicado: (2021)

COVID-19 pandemic and patients with cancer: The protocol of a Clinical Oncology center in Tehran, Iran
por: Rakhsha, Afshin, et al.
Publicado: (2020)

Decision on Chemotherapy Amidst COVID-19 Pandemic: a Review and a Practical Approach from Iran
por: Rakhsha, Afshin, et al.
Publicado: (2020)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Neutrophil-to-Lymphocyte Ratio (NLR) as a Poor Predictive Biomarker for Pathological Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study
por: Novin, Kambiz, et al.
Publicado: (2023)

Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer
por: Melotek, James M., et al.
Publicado: (2016)

Successful Treatment of Central Nervous System Histiocytic Sarcoma With Craniectomy and Adjuvant Radiotherapy
por: Shahrokh, Soroush, et al.
Publicado: (2022)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

A prospective randomized study comparing concurrent chemoradiation with weekly and 3 weekly cisplatin in locally advanced oropharyngeal carcinoma
por: Nanda, R., et al.
Publicado: (2019)

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis
por: Lee, So Yeon, et al.
Publicado: (2018)

Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2023)

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

Randomized, Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105, HERBIS‐4A Trial
por: Kawakami, Hisato, et al.
Publicado: (2018)

Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer
por: Han, Hye Ri, et al.
Publicado: (2021)

Neuroendocrine carcinoma of the ovotestis: A case report and review of literatures
por: Ashrafganjoei, Tahereh, et al.
Publicado: (2016)

Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial
por: Li, Jing, et al.
Publicado: (2022)

The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
por: Kong, Tae Wook, et al.
Publicado: (2012)

Commentary on “Weekly Low‐Dose Versus Three‐Weekly High‐Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non‐Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta‐Analysis of Aggregate Data”
por: Colevas, A. Dimitrios
Publicado: (2017)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Tousif, Devale, et al.
Publicado: (2020)

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)
por: Koizumi, Wasaburo, et al.
Publicado: (2015)

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial
por: Brunt, A. Murray, et al.
Publicado: (2016)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)
por: Guan, Jian, et al.
Publicado: (2016)

Three weekly versus weekly concurrent cisplatin: safety propensity score analysis on 166 head and neck cancer patients
por: Buglione, Michela, et al.
Publicado: (2021)

P34.01 6-Weekly vs 3-Weekly Pembrolizumab – Toxicities and Tolerance in The COVID-era
por: Douglas, C., et al.
Publicado: (2021)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Head and Neck Squamous Cell Carcinoma in Iran: Clinico-Pathological and Treatment-Related Factors Influencing Survival
por: Novin, Kambiz, et al.
Publicado: (2015)

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis
por: Helfenstein, Seth, et al.
Publicado: (2019)

Reducing Virus Transmission from Heating, Ventilation, and Air Conditioning Systems of Urban Subways
por: Nazari, Ata, et al.
Publicado: (2022)

Standard 6-week chemoradiation for elderly patients with newly diagnosed glioblastoma
por: Vaugier, Loïg, et al.
Publicado: (2021)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
por: Brandberg, Yvonne, et al.
Publicado: (2020)

Effects of an 8-week yoga program on sustained attention and discrimination function in children with attention deficit hyperactivity disorder
por: Chou, Chien-Chih, et al.
Publicado: (2017)

Jet fans in the underground car parking areas and virus transmission
por: Nazari, Ata, et al.
Publicado: (2021)

The powerful immune system against powerful COVID-19: A hypothesis
por: Taghizadeh-Hesary, Farzad, et al.
Publicado: (2020)

COVID-19 induced liver injury from a new perspective: Mitochondria
por: Akbari, Hassan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e1die38ivugf3sos7ol73fsa8q